Thienopyrimidine inhibitors of farnesyl and/or geranylgeranyl pyrophosphate synthase

A compound of formula I:

• or a pharmaceutically acceptable salt or solvate thereof, wherein
• X═O, NR4, or CR4R4;
• R2 is selected from H, C1-6alkyl, C3-6 cycloalkyl, C6-10aryl, 3-10 membered heterocycle, —CONHR7, —SO2NHR7;
• R3 is selected from CH[PO(OH)2]2;
• CH2PO(OH)2;
• CHR7PO(OH)2;
• CH(CO2H)2;
• CH(SO2NHR7)PO(OH)2;
• CR8R9-SO2NR7(PO(OH)2), COCO2H;
• CR8(PO(OH)2)2, CR8R9CO2H;
• CR8R9PO(OH)2, CR8R9COR10 or C1-6alkyl;
• R4 are each independently H, C1-6alkyl, aryl or 3-10 membered heterocycle;
• R5 and R6 are independently selected from H, C1-6alkyl, optionally substituted C3-6 cycloalkyl, optionally substituted C6-10aryl, optionally substituted 3-10 membered heterocycle, CH2OH, CO2H, CH2CO2H, (CH2)nPO(OH)2, (CH2)n-SO2NR7(PO(OH)2), (CH2)nSO2NR7R8, NR7R8, NH(CH2), PO(OH)2, NO2 or OR7;
• where n is an integer number from 1-3;
• R5 and R6 can also be independently selected from amino acids, natural or unnatural attached to thienopyrimidine core via a C-1-4 alkyl linker;
• R7, R8 and R9 are each independently —H, —C1-6 alkyl, —C3-6 cycloalkyl, —C6-10 aryl, 3-10 membered heterocycle or —C1-6alkyl-C6-10aryl;
• R8 and R9 can also be taken together to form a 3 to 6 membered cycoalkyl;
• and
• R10 is C1-6 alkyl, —C3-6 cycloalkyl, —C6-10 aryl or 3-10 membered heterocycle.